Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12434854 | 0.94 | HDAC1 (0.82) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL2206679 | 0.93 | HDAC1 (0.80) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL2209480 | 0.91 | HDAC1 (0.79) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL4311538 | 0.91 | HDAC1 (0.81) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL8220683 | 0.90 | HDAC1 (0.80) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL2208371 | 0.90 | HDAC1 (0.81) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL8101991 | 0.89 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL2210657 | 0.89 | HDAC1 (0.82) | HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL4323563 | 0.88 | HDAC1 (1.00) | HDAC1HDAC2HDAC3 | |
| SCHEMBL8100188 | 0.88 | HDAC1 (1.00) | HDAC1HDAC2HDAC3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009544611-A | — | — | 2009-12-17 | — | — | JP | claimed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | claimed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, PPM1A, PTEN | HDAC1 4/4885HDAC2 8/4885HDAC3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.